Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference
Aptose Biosciences, a clinical-stage biotechnology firm, will attend the RBC Capital Markets Global Healthcare Virtual Conference on May 20, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aptose Biosciences, a clinical-stage biotechnology firm, will attend the RBC Capital Markets Global Healthcare Virtual Conference on May 20, 2020. Their presentation is scheduled from 3:40 to 4:05 pm EDT. The event will include investor meetings and a fireside chat format. Aptose focuses on developing personalized cancer therapies, notably two agents in clinical trials: CG-806, a first-in-class kinase inhibitor for hematologic malignancies, and APTO-253, targeting the MYC oncogene for acute myeloid leukemia.
Details
News Market Reaction – APTO
The recorded move for APTO in the trading session of this news was +5.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold investor meetings at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020.
Conference Presentation Details:
Date: Wednesday, May 20, 2020
Time: 3:40 – 4:05 pm EDT
Location: Virtual, Fireside Chat
Webcast: link
The webcast and presentation will be archived shortly after the live event and will be available on the Aptose website here.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.com.
For further information, please contact:
| Aptose Biosciences Inc. | LifeSci Advisors, LLC |
| Greg Chow | Dan Ferry, Managing Director |
| Executive Vice President, CFO | 617-535-7746 |
| 650-718-5028 | Daniel@LifeSciAdvisors.com |
| gchow@aptose.com | |
| SMP Communications | |
| Susan Pietropaolo | |
| 201-923-2049 | |
| susan@smpcommunications.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.